Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Oct
18
2021
California Broadens Security and Breach Laws, Includes Genetic Data Sheppard, Mullin, Richter & Hampton LLP
Jan
4
2022
Cannabis Legislation Year-in-Review Sheppard, Mullin, Richter & Hampton LLP
Oct
8
2013
Governor Brown Signs Senate Bill 4 Regulating Hydraulic Fracturing Well Stimulation Treatments Sheppard, Mullin, Richter & Hampton LLP
Feb
11
2022
Federal Cannabis Reform – Is 2022 the Year? Sheppard, Mullin, Richter & Hampton LLP
Apr
4
2022
The House Does It Again: MORE Act Ready for Senate Action Sheppard, Mullin, Richter & Hampton LLP
Jun
13
2022
States Target Infant Formula Price Gouging Sheppard, Mullin, Richter & Hampton LLP
Feb
11
2019
HHS Proposes Rule to Eliminate Safe Harbor for PBM Drug Rebates Sheppard, Mullin, Richter & Hampton LLP
Jun
27
2022
PFAS Regulations Could Open Floodgates to Prop 65 Enforcement – Assess & Manage Your Exposure Now Sheppard, Mullin, Richter & Hampton LLP
Mar
21
2019
E-Cig Company Settles Online Behavioral Advertising Inquiry Sheppard, Mullin, Richter & Hampton LLP
Nov
21
2014
Faulty Damages Model Leads to Partial Decertification in California Sheppard, Mullin, Richter & Hampton LLP
Jul
29
2019
CBO Report Shows Senate’s Bipartisan Bill on Surprise Billing, Drug Prices, Transparency, and More Would Result in Deficit Decrease Sheppard, Mullin, Richter & Hampton LLP
Mar
29
2023
FDA Issues First Untitled Letter of the Year to HCT/P Manufacturer Sheppard, Mullin, Richter & Hampton LLP
Apr
5
2016
Challenge to California Ordinance Prohibiting Mobile Medical Marijuana Dispensaries Goes Up in Smoke Sheppard, Mullin, Richter & Hampton LLP
Dec
13
2023
Federal Circuit Evaluates Impact of the Final Written Decision (FWD) in a Parallel Inter-Partes Review (IPR) on District Court’s decision of Invalidity and Infringement Sheppard, Mullin, Richter & Hampton LLP
Jan
18
2024
Federal Circuit Affirms Skinny Label Carve Outs Sheppard, Mullin, Richter & Hampton LLP
Feb
29
2024
District Court Elucidates the Meaning of “to Induce” Under the Federal Health Care Program Anti-Kickback Statute Sheppard, Mullin, Richter & Hampton LLP
May
9
2024
Bridging the Gap: Cannabis Rescheduling to Align Policy with Research Sheppard, Mullin, Richter & Hampton LLP
Feb
10
2021
Federal Circuit Agrees to Reconsider Ruling in GSK v. Teva Drug Patent Case Sheppard, Mullin, Richter & Hampton LLP
Jul
14
2010
Elimination of Customs Duties Possible for Over 700 Additional Pharmaceutical Products and Chemical Intermediates Sheppard, Mullin, Richter & Hampton LLP
Jan
10
2018
WARNING: Prop 65 Has Changed – If Your Product Is Sold In California Or You Do Business In California, Pay Attention Sheppard, Mullin, Richter & Hampton LLP
Jan
19
2018
WARNING: There Are New Warning Requirements for Imports Sold in California Sheppard, Mullin, Richter & Hampton LLP
Jul
2
2021
340B Drug Pricing Discount Program Update: HRSA Now Demands That Drug Manufacturers Provide 340B Discounts To Contract Pharmacies Amid Ongoing Litigation Sheppard, Mullin, Richter & Hampton LLP
Sep
29
2021
Impact of NYC’s New Delivery Service Data Sharing Requirement Sheppard, Mullin, Richter & Hampton LLP
Sep
12
2018
Brady v. Bayer Corp: One A Day Will Not Keep Plaintiffs Away Sheppard, Mullin, Richter & Hampton LLP
Nov
20
2018
Blog Series Part 7: CMS Proposed Rule on Policy and Technical Changes to the Medicare Advantage, Medicare Prescription Drug Benefit, Medicaid Fee-For-Service, and Medicaid Managed Care Programs for 2020 and 2021 Sheppard, Mullin, Richter & Hampton LLP
Apr
18
2022
China Proposed Draft Implementing Rules for Human Genetic Resources Management Sheppard, Mullin, Richter & Hampton LLP
May
19
2022
FDA White Paper Signals Shift to Performance-Based Reviews of Mature Quality Systems Sheppard, Mullin, Richter & Hampton LLP
Jun
19
2014
Supreme Court Rules Compliance with Food and Drug Administration (FDA) Labeling Guidelines Does Not Bar Lanham Act False Advertising Suits – POM Wonderful v. Coca-Cola Co. Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins